On October 20, 2022 Zymeworks Inc. ("Zymeworks" or the "Company") (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported the highlights from its early R&D Day reviewing the Company’s progress and plans for the development of its novel pipeline assets and applications of its proprietary next-generation technology platforms (Press release, Zymeworks, OCT 20, 2022, View Source [SID1234622240]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This event is an important opportunity for us to provide an update on our progress in developing the next generation of innovative therapeutics based on our proprietary engineering platforms and integrated technologies," said Kenneth Galbraith, Chair and CEO of Zymeworks. "During the program we will review recent data related to our antibody drug conjugates (ADC) and multi-specific antibody therapeutics (MSAT). Our goal at Zymeworks is to submit five Investigational Drug Applications in the next five years, and we believe today’s early R&D Day will demonstrate that we have the momentum, expertise, and resources in place to be successful in developing the next wave of potential best-in-class therapeutics."
The event will include presentations on ADC and MSAT research programs and emerging pipeline candidates that expand the Company’s focus on cancer indications with significant unmet patient needs. Similarly, the event will highlight the future development path and strategy that we believe will help drive the next advances in antibody-based therapeutics.
Presenters will include:
Paul Moore, Ph.D., Chief Scientific Officer
Stuart Barnscher, Director, Preclinical Programs, ADC Therapeutics Development
Jamie Rich, Ph.D., Director, Technology, ADC Therapeutic Development
Thomas Spreter Von Kreudenstein, Ph.D., Director, Protein Engineering
Nina Weisser, Ph.D., Director, Multispecific Antibody Therapeutics
"Our team is excited to have the opportunity to share these important updates and provide insight into the future in antibody-based therapeutics we are pursuing at Zymeworks," said Paul Moore, Ph.D., Chief Scientific Officer of Zymeworks. "The use of our advanced technology platforms and continued scientific advancements in both protein engineering and antibody conjugation brings us further towards our goal of addressing difficult to treat cancers with traditionally poor patient prognosis."
Zymeworks Early R&D Day Program Highlights
Update on the Company’s ADC programs, including:
Topoisomerase 1 inhibitor (TOPO1i) payload
ZW191– a Folate Receptor-alpha targeted topoisomerase-1 ADC
ZW251 – a Glypican-3 targeted topoisomerase-1 ADC
ZW220 – a NaPi2b targeted topoisomerase-1 ADC
Review of progress in MSAT development, including:
ZW171– a Mesothelin x CD3 targeted 2+1 format bispecific antibody
Tri-specific T-cell Engagers incorporating co-stimulation (TriTCE-costim)
Tri-specific T-cell Engagers incorporating checkpoint inhibition (TriTCE-CPI)
Early R&D Day Webcast Information
A live webcast of the Company’s Early R&D Day event will be available on the Investors & Media section of Zymeworks’ website, www.zymeworks.com. A replay of the webcast will be available following the presentation.